
‘More options’ flood IBD market as rival IL-23 drugs face off with Stelara biosimilar boom
Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key Takeaways: Three new IL-23 inhibitors have been approved …